AP611074 + Placebo
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anogenital Warts
Conditions
Anogenital Warts, Condylomata Acuminata, Human Papillomavirus Infection
Trial Timeline
Feb 28, 2012 → May 6, 2013
NCT ID
NCT01532102About AP611074 + Placebo
AP611074 + Placebo is a phase 1/2 stage product being developed by Vaxart for Anogenital Warts. The current trial status is completed. This product is registered under clinical trial identifier NCT01532102. Target conditions include Anogenital Warts, Condylomata Acuminata, Human Papillomavirus Infection.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01532102 | Phase 1/2 | Completed |
Competing Products
3 competing products in Anogenital Warts
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Topical NO + Placebo | Kyowa Kirin | Phase 2 | 52 |
| V501 | Merck | Phase 3 | 77 |
| V501 + Placebo | Merck | Phase 3 | 77 |